Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

被引：5
|
作者：
Zhou, C. [1 ]
Lu, Y. [2 ]
Kim, S-W. [3 ]
Baisamut , T. [4 ]
Zhou, J. [5 ]
Zhang, Y. [6 ]
He, J. [7 ]
Yang, J. [8 ]
Cheng, Y. [9 ]
Lee, S-H. [10 ]
Chang, J. [11 ]
Fang, J. [12 ]
Liu, Z. [13 ]
Bu, L. [14 ]
Qian, L. [15 ]
Xu, T. [15 ]
Archer, V. [16 ]
Hilton, M. [17 ]
Zhou, M. [18 ]
Zhang, L. [19 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[6] Zhejiang Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China
[7] Guangzhou Med Univ, Dept Thorac Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[9] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[11] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Canc Hosp, Shenzhen, Peoples R China
[12] Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[13] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China
[14] Roche Pharma Dev, Dept Data Sci, Shanghai, Peoples R China
[15] Roche Pharma Dev, Dept Clin Sci, Shanghai, Peoples R China
[16] Roche Prod Ltd, Prod Dev, Welwyn Garden City, Herts, England
[17] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Basel, Switzerland
[18] Roche Pharma Dev, Dept Safety, Shanghai, Peoples R China
[19] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA11
引用
收藏
页码：S1563 / S1563
页数：1
相关论文
共 50 条
  • [31] Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK1) non-small cell lung cancer (NSCLC) patients (Pts)
    Reckamp, K. L.
    Lee, J.
    Huang, J.
    Proskorovsky, I.
    Reichmann, W.
    Krotneva, M.
    Kerstein, D.
    Huang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).
    Goto, Koichi
    Yang, James Chih-Hsin
    Kim, Dong-Wan
    Lu, Shun
    Seto, Takashi
    Yang, Jin-Ji
    Yamamoto, Noboru
    Ahn, Myung-Ju
    Takahashi, Toshiaki
    Yamanaka, Takeharu
    Kemner, Allison Margaret
    Roychowdhury, Debasish
    Paolini, Jolanda
    Wilner, Keith D.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK plus NSCLC.
    Camidge, D. Ross
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Cheema, Parneet K.
    Pavlakis, Nick
    De Marinis, Filippo
    Stroyakovskiy, Daniil L.
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Zeaiter, Ali Hassan
    Mitry, Emmanuel
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB COMPARED TO CHEMOTHERAPY FOR THE TREATMENT OF TREATMENT-NAIVE PATIENTS WITH ALK POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
    Kourkoulas, N.
    Kyriopoulos, D.
    Athanasakis, K.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [35] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Hoffknecht, Petra
    Mok, Tony
    Shaw, Alice I.
    Camidge, D. Ross
    Gadgeel, Shirish
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [36] Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK plus non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
    Solomon, Benjamin J.
    Liu, Geoffrey
    Felip, Enriqueta
    Mok, Tony S. K.
    Soo, Ross Andrew
    Mazieres, Julien
    Shaw, Alice Tsang
    de Marinis, Filippo
    Goto, Yasushi
    Wu, Yi-Long
    Kim, Dong-Wan
    Martini, Jean-Francois
    Messina, Rossella
    Paolini, Jolanda
    Polli, Anna
    Thomaidou, Despina
    Toffalorio, Francesca
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8503 - LBA8503
  • [37] BUDGET IMPACT OF ALECTINIB IN THE TREATMENT OF NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
    Kourkoulas, N.
    Kyriopoulos, D.
    Athanasakis, K.
    VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
  • [38] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial
    Ahn, Myung-Ju
    Camidge, D. Ross
    Tiseo, Marcello
    Reckamp, Karen L.
    Hansen, Karin Holmskov
    Kim, Sang-We
    Huber, Rudolf M.
    West, Howard Jack
    Groen, Harry J. M.
    Hochmair, Maximilian J.
    Leighl, Natasha B.
    Gettinger, Scott N.
    Langer, Corey J.
    Paz-Ares, Luis G.
    Smit, Egbert F.
    Kim, Edward S.
    Reichmann, William
    Kerstein, David
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Wilner, K.
    Usari, T.
    Polli, A.
    Kim, E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S133 - S133
  • [40] A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK plus Non-small Cell Lung Cancer (NSCLC)
    Shi, Y.
    Chen, J.
    Yang, R.
    Wu, H.
    Wang, Z.
    Yang, W.
    Cui, J.
    Zhang, Y.
    Liu, C.
    Cheng, Y.
    Liu, Y.
    Shan, J.
    Wang, D.
    Yang, L.
    Hu, C.
    Zhao, J.
    Cao, R.
    Tan, B.
    Xu, K.
    Si, M.
    Li, H.
    Mao, R.
    Li, L.
    Kang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S50
12345